NEW YORK , Dec. 14, 2022 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (Nasdaq:SIOX) today announced that its Board of Directors has determined, after extensive and careful consideration of potential strategic alternatives, that it is in the best interests of the Company and its shareholders to
- Three-Month and Six-Month Losses decline by 85.5% and 65.3%, respectively - Operating Cash Outflows for the Six Months Ended September 30, 2022 decreased by $8.1 million or 37% versus the prior year period - Strong cash position with $49.86 million of cash and cash equivalents as of September 30,
— Strong cash position with $54.8 million of cash and cash equivalents as of June 30, 2022 , expected to provide cash runway beyond August 2023 NEW YORK, N.Y. and DURHAM, N.C. , Aug. 11, 2022 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX) today provided financial results for its fiscal
NEW YORK and DURHAM, N.C. , June 14, 2022 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX) today provided financial results for its fiscal year ended March 31, 2022 . Fiscal Fourth Quarter Financial Summary For the fourth fiscal quarter ended March 31, 2022 , research and development
-Company Announces Termination of Licensing Agreement for GM1 and GM2 Gene Therapies with the University of Massachusetts -Company has engaged SVB Securities to advise it on a range of strategic alternatives to maximize stockholder value -Company had cash and cash equivalents of approximately $64
Company prioritizing industry-leading clinical-stage programs, AXO-AAV-GM1 and AXO-AAV-GM2, the first potential disease-modifying therapies for GM1 gangliosidosis and Tay-Sachs/Sandhoff disease $81.9 million of cash and cash equivalents as of December 31, 2021 , providing expected cash runway into
NEW YORK and DURHAM, N.C., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases, today announced that it will present data in an oral
– Company to prioritize industry-leading clinical-stage programs, AXO-AAV-GM1 and AXO-AAV-GM2, the first potential disease-modifying therapies for GM1 gangliosidosis and Tay-Sachs/Sandhoff disease, respectively; and to terminate AXO-Lenti-PD license agreement with Oxford Biomedica for Parkinson’s
